{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:50:56Z","timestamp":1771469456375,"version":"3.50.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.02.009","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T14:50:25Z","timestamp":1306421425000},"page":"S101-S110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S1","title":["Outcome of Treatment of Chronic Myeloid Leukemia With Second-Generation Tyrosine Kinase Inhibitors After Imatinib Failure"],"prefix":"10.1016","volume":"11","author":[{"given":"A. Megan","family":"Cornelison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.02.009_bib1","first-page":"169","article-title":"Chronic myelogenous leukemia: update on biology and treatment","volume":"2","author":"Faderl","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2011.02.009_bib2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJMct071828","article-title":"BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia","volume":"357","author":"Schiffer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib3","first-page":"205","article-title":"Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia","volume":"3","author":"Ramchandren","year":"2009","journal-title":"Biologics: Targets & Therapy"},{"key":"10.1016\/j.clml.2011.02.009_bib4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib5","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V82.6.1838.1838","article-title":"Role of p21 RAS in p210 BCR-ABL transformation of murine myeloid cells","volume":"82","author":"Mandanas","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib6","first-page":"1111","article-title":"Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1","volume":"22","author":"Okuda","year":"1994","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2011.02.009_bib7","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The BCR-ABL leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clml.2011.02.009_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.02.009_bib9","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.02.009_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR\/ABL","volume":"183","author":"Carlesso","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2011.02.009_bib11","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190 (BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.02.009_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-2-10","article-title":"New dosing schedules of dasatinib for CML and adverse event management","volume":"2","author":"Wong","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib14","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib15","first-page":"1972","article-title":"Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.02.009_bib16","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.12265","article-title":"Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.02.009_bib17","series-title":"Gleevec \u00ae[package insert]","year":"2007"},{"key":"10.1016\/j.clml.2011.02.009_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11523-008-0100-y","article-title":"Treatment selection after imatinib resistance in chronic myeloid leukemia","volume":"4","author":"Jabbour","year":"2009","journal-title":"Targ Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib21","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib24","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-a plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-a-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib26","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib27","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.02.009_bib28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib30","first-page":"46176","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematology Am Soc of Hematology Educ Program"},{"key":"10.1016\/j.clml.2011.02.009_bib31","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.009_bib32","first-page":"5","article-title":"Medial management of CML","volume":"371","author":"Shah","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2011.02.009_bib33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.biocel.2007.10.001","article-title":"Overcoming kinase resistance in chronic myeloid leukemia","volume":"40","author":"Lee","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.clml.2011.02.009_bib34","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.clml.2011.02.009_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib36","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.009_bib37","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.009_bib38","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.02.009_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","author":"Shah","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2011.02.009_bib40","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib41","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib42","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemia cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib43","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib44","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clml.2011.02.009_bib45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0304-3835(02)00359-2","article-title":"Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiaxipine derivative, JTV-519","volume":"187","author":"Che","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clml.2011.02.009_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0304-3835(03)00338-0","article-title":"Anti-proliferative effect of the ABL tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562\/ADM cell line","volume":"199","author":"Kotaki","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clml.2011.02.009_bib47","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exphem.2005.03.014","article-title":"RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines","volume":"33","author":"Rumpold","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2011.02.009_bib48","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib49","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib50","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood.V112.11.3187.3187","article-title":"CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose","volume":"112","author":"White","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2011.02.009_bib52","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":"Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the ABL inhibitor STI571","volume":"92","author":"Gambacorti-Passerini","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2011.02.009_bib53","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.02.009_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clml.2011.02.009_bib55","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and on-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2011.02.009_bib57","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib58","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.02.009_bib59","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib60","unstructured":"Sprycel\u00ae (dasatinib), Princeton, NJ: [package insert]. 2007."},{"key":"10.1016\/j.clml.2011.02.009_bib61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.02.009_bib62","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/jco.2008.26.15_suppl.7009","article-title":"Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML_CP) with resistance or intolerance to imatinib (START-C)","volume":"26","author":"Mauro","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib63","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1200\/jco.2007.25.18_suppl.7004","article-title":"Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib64","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib65","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib66","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib67","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib68","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood-2008-09-180604","article-title":"Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia","volume":"114","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib69","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib70","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-07-5015","article-title":"Nilotinib","volume":"14","author":"Deininger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.02.009_bib71","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2011.02.009_bib72","first-page":"256","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study","volume":"94","author":"Hochhaus","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.02.009_bib73","doi-asserted-by":"crossref","first-page":"17501","DOI":"10.1200\/jco.2007.25.18_suppl.17501","article-title":"Incidence of grade 3\/4 adverse events in imatinib resistant\/intolerant chronic phase CML (CP-CML): A comparison of nilotinib and dasatinib","volume":"25","author":"Carpiuc","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib74","first-page":"7039","article-title":"Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP)","volume":"25","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib75","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.V112.11.1098.1098","article-title":"Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib76","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V114.22.643.643","article-title":"A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib77","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.V114.22.861.861","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors- results of a multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib78","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V114.22.644.644","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation- results of an ongoing multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib79","doi-asserted-by":"crossref","unstructured":"Cortes JE, Wetzler M, Lipton J, et al. Subcutaneous omacetaxine (OM) treatment of chronic phase (cp) chronic myeloid leukemia (CML) patients following multiple tyrosine kinase inhibitor (TKI) Failure. Program and abstracts of the 52nd American Society of Hematology Annual Meeting and Exposition; December 4-7, 2010; Orlando, Florida. Abstract 2290.","DOI":"10.1182\/blood.V116.21.2290.2290"},{"issue":"suppl","key":"10.1016\/j.clml.2011.02.009_bib80","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.V112.11.186.186","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib81","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.02.009_bib82","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib83","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib84","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib86","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib87","first-page":"51","article-title":"Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia","volume":"24","author":"Soverini","year":"2006","journal-title":"Blood"},{"issue":"suppl B","key":"10.1016\/j.clml.2011.02.009_bib88","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib89","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib90","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V114.22.643.643","article-title":"A Phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib91","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V114.22.644.644","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"issue":"suppl D","key":"10.1016\/j.clml.2011.02.009_bib92","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V114.22.3298.3298","article-title":"Prognostic factors for progression-free survival in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24 month data","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib93","first-page":"210","article-title":"Predictive factors for response and outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib94","doi-asserted-by":"crossref","first-page":"680s","DOI":"10.1200\/jco.2007.25.18_suppl.17503","article-title":"Pleural effusions in patients treated with dasatinib: results from two institutions, risk factors and management","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib95","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood.V114.22.1129.1129","article-title":"Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes","volume":"114","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib96","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib97","doi-asserted-by":"crossref","unstructured":"Guilhot F. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML group (FI LMC). Blood 2008;112-(abstr):183","DOI":"10.1182\/blood.V112.11.183.183"},{"key":"10.1016\/j.clml.2011.02.009_bib98","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Niltonib as front-line therapy for patients with chronic myeloid lekemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib99","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.V116.21.359.359","article-title":"Excellent outcomes at 3 years with Nilotinib 800 mg daily in early chronic phase, Ph(+) chronic myeloid leukemia (CML): results of a phase 2 GIMEMA CML WP clinical trial","volume":"116","author":"Rosti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib100","doi-asserted-by":"crossref","unstructured":"Hughes TP, Hochhaus A, Saglio G, et al. ENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood YEAR; XXX(abstr):207","DOI":"10.1182\/blood.V116.21.207.207"},{"key":"10.1016\/j.clml.2011.02.009_bib101","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.009_bib102","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.009_bib103","doi-asserted-by":"crossref","unstructured":"Shah N, Kantarjian HM, Hochhaus A, et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up. Program and abstracts of the 52nd American Society of Hematology Annual Meeting and Exposition; December 4-7, 2010; Orlando, Florida. Abstract 206","DOI":"10.1182\/blood.V116.21.206.206"},{"key":"10.1016\/j.clml.2011.02.009_bib104","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood.V116.21.LBA-6.LBA-6","article-title":"A randomized phase II trial of dasatinib 100 Mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup Trial","volume":"116","author":"Radich","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.009_bib105","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Kim DW, Kantarjian HM, et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Program and abstracts of the 52nd American Society of Hematology Annual Meeting and Exposition; December 4-7, 2010; Orlando, Florida. Abstract 208","DOI":"10.1182\/blood.V116.21.208.208"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:12Z","timestamp":1761870072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":104,"alternative-id":["S2152265011000450"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.02.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of Treatment of Chronic Myeloid Leukemia With Second-Generation Tyrosine Kinase Inhibitors After Imatinib Failure","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}